Characterisation of BiologIC’s 3D printed biocomputer platform for advanced therapies, cellular agriculture and diagnostics

生物科技公司正在开发世界上第一台利用基础IP和最新的添加剂制造(3D打印)技术的生物计算机。第一代生物计算机正在开发中，以推进诊断、先进治疗、新疫苗和培养肉类的应用，并旨在为下一代合成生物学提供大规模动力。我们使用3D打印作为生物计算机平台的制造工艺。多材料3D打印实现了材料(聚合物和弹性体)的数字混合，使我们能够生产一个将流体、电子、光学和气动集成到一个系统中的单一系统。将这些系统引入受监管的市场(如先进疗法的制造)的挑战之一是控制材料。生物公司已经开发了关于3D打印系统在其技术的每一层上的生物兼容性的专有技术。以前的工作已经表明，生物的后处理方法可以有效地提高3D打印系统的生物兼容性，使分子和细胞生物学应用成为可能，尽管需要进一步的优化。通过该项目与外部专业人员的合作，生物将表征进一步开发生物计算机平台所需的3D打印组件，这将使合成生物学、先进疗法和诊断的生产发生范式转变。

BiologIC Technologies is developing the first world's biocomputer leveraging foundational IP and the latest additive manufacturing (3D printing) technologies. The first generation of the biocomputer is being developed to advance applications in diagnostics, advanced therapies, new vaccines and cultured meat and is designed to power the next generation of synthetic biology at scale.We use 3D printing as the fabrication process of the biocomputer platform. Multi-material 3D printing enables digital blending of materials (polymers and elastomers) that lets us produce a single system that integrates fluidics, electronics, optics and pneumatics into a single system.One of the challenges in bringing these systems to regulated markets such as manufacturing of advanced therapies is controlling the materials. BiologIC has developed proprietary knowhow regarding biocompatibility of the 3D printed system across each layer of its technology. Previous work has shown that BiologIC's post-processing methodologies can efficiently increase the biocompatibility of the 3D printed systems enabling molecular and cellular biology applications although further optimisation is desirable.By collaborating with external expertise through this project BiologIC will characterise the 3D printed components necessary for the further development of the biocomputer platform that will enable a paradigm shift in the production of synthetic biology, advanced therapies and diagnostics.